[Treatment of hypertrophic obstructive cardiomyopathy with verapamil, a calcium antagonist (author's transl)].
Cardiac catheterisation with pressure measurements, left-ventricular cine-angiography and selective coronary angiography confirmed the diagnosis of hypertrophic obstructive cardiomyopathy in 20 patients. After a mean observation period of 20 months during which most of them were treated with beta-blockers, verapamil, 480 mg by mouth, was given for an average of 12 months. There was an impressive improvement in symptoms, compared with the state under beta-blocker treatment. There was a significant reduction in the ECG signs of left-ventricular hypertrophy and of the radiologically measured heart volume. Treatment of this condition with verapamil appeared to be superior to that with beta-blockers.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D002118:Calcium / Q000037:antagonists & inhibitors*; D002306:Cardiac Volume; D002312:Cardiomyopathy, Hypertrophic / Q000188:drug therapy* / Q000503:physiopathology; D004341:Drug Evaluation; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D014700:Verapamil / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D014700:Verapamil; D002118:Calcium
Calciumantagonistische Therapie bei hypertroph-obstruktiver Kardiomyopathie